The Biological Function of the Huntingtin Protein and Its Relevance to Huntington's Disease Pathology

Overview

Journal Curr Trends Neurol

Date 2011 Dec 20

PMID 22180703

Citations 91

Authors

Joost Schulte

J Troy Littleton

Affiliations

Soon will be listed here.

Abstract

Huntington's Disease is an adult-onset dominant heritable disorder characterized by progressive psychiatric disruption, cognitive deficits, and loss of motor coordination. It is caused by expansion of a polyglutamine tract within the N-terminal domain of the Huntingtin protein. The mutation confers a toxic gain-of-function phenotype, resulting in neurodegeneration that is most severe in the striatum. Increasing experimental evidence from genetic model systems such as mice, zebrafish, and Drosophila suggest that polyglutamine expansion within the Huntingtin protein also disrupts its normal biological function. Huntingtin is widely expressed during development and has a complex and dynamic distribution within cells. It is predicted to be a protein of pleiotropic function, interacting with a large number of effector proteins to mediate a host of physiological processes. In this review, we highlight the wildtype function of Huntingtin, focusing on its postdevelopmental roles in axonal trafficking, regulation of gene transcription, and cell survival. We then discuss how potential loss-of-function phenotypes resulting in polyglutamine expansion within Huntingtin may have direct relevance to the underlying pathophysiology of Huntington's Disease.

Citing Articles

The Role of MicroRNAs in Neurodegeneration: Insights from Huntington's Disease.

Mansour R, Shaker A, Abulsoud A, Mageed S, Ashraf A, Elsakka E Mol Neurobiol. 2025; .

PMID: 40009259 DOI: 10.1007/s12035-025-04750-7.

Glutamine missense suppressor transfer RNAs inhibit polyglutamine aggregation.

Tennakoon R, Bily T, Hasan F, Syal S, Voigt A, Balci T Mol Ther Nucleic Acids. 2025; 36(1):102442.

PMID: 39897579 PMC: 11787650. DOI: 10.1016/j.omtn.2024.102442.

Reactive Oxygen Species: Angels and Demons in the Life of a Neuron.

Biswas K, Alexander K, Francis M NeuroSci. 2024; 3(1):130-145.

PMID: 39484669 PMC: 11523706. DOI: 10.3390/neurosci3010011.

Epigenetics in rare neurological diseases.

Roberts C, Arezoumand K, Kadar Shahib A, Davie J, Rastegar M Front Cell Dev Biol. 2024; 12:1413248.

PMID: 39108836 PMC: 11300358. DOI: 10.3389/fcell.2024.1413248.

Protein modification in neurodegenerative diseases.

Ramazi S, Dadzadi M, Darvazi M, Seddigh N, Allahverdi A MedComm (2020). 2024; 5(8):e674.

PMID: 39105197 PMC: 11298556. DOI: 10.1002/mco2.674.

References

Sahlender D, Roberts R, Arden S, Spudich G, Taylor M, Luzio J . Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis. J Cell Biol. 2005; 169(2):285-95. PMC: 2171882. DOI: 10.1083/jcb.200501162. View

Li Z, Karlovich C, Fish M, Scott M, Myers R . A putative Drosophila homolog of the Huntington's disease gene. Hum Mol Genet. 1999; 8(9):1807-15. DOI: 10.1093/hmg/8.9.1807. View

Hockly E, Richon V, Woodman B, Smith D, Zhou X, Rosa E . Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2003; 100(4):2041-6. PMC: 149955. DOI: 10.1073/pnas.0437870100. View

Tartari M, Gissi C, Lo Sardo V, Zuccato C, Picardi E, Pesole G . Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. Mol Biol Evol. 2007; 25(2):330-8. DOI: 10.1093/molbev/msm258. View

Baxendale S, Abdulla S, Elgar G, Buck D, Berks M, Micklem G . Comparative sequence analysis of the human and pufferfish Huntington's disease genes. Nat Genet. 1995; 10(1):67-76. DOI: 10.1038/ng0595-67. View

Cattaneo E, Zuccato C, Tartari M . Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci. 2005; 6(12):919-30. DOI: 10.1038/nrn1806. View

Sapp E, Schwarz C, Chase K, Bhide P, Young A, Penney J . Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol. 1997; 42(4):604-12. DOI: 10.1002/ana.410420411. View

Guidetti P, Charles V, Chen E, Reddy P, Kordower J, Whetsell Jr W . Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol. 2001; 169(2):340-50. DOI: 10.1006/exnr.2000.7626. View

Mai A, Rotili D, Valente S, Kazantsev A . Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des. 2009; 15(34):3940-57. DOI: 10.2174/138161209789649349. View

10.

Qin Z, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden M . Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci. 2004; 24(1):269-81. PMC: 6729557. DOI: 10.1523/JNEUROSCI.1409-03.2004. View

11.

Paulsen J, Nopoulos P, Aylward E, Ross C, Johnson H, Magnotta V . Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010; 82(3-4):201-7. PMC: 2892238. DOI: 10.1016/j.brainresbull.2010.04.003. View

12.

Chang D, Rintoul G, Pandipati S, Reynolds I . Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis. 2006; 22(2):388-400. DOI: 10.1016/j.nbd.2005.12.007. View

13.

Gofflot F, Chartoire N, Vasseur L, Heikkinen S, Dembele D, Le Merrer J . Systematic gene expression mapping clusters nuclear receptors according to their function in the brain. Cell. 2007; 131(2):405-18. DOI: 10.1016/j.cell.2007.09.012. View

14.

MAXWELL M . RNAi applications in therapy development for neurodegenerative disease. Curr Pharm Des. 2009; 15(34):3977-91. DOI: 10.2174/138161209789649295. View

15.

Powers W, Videen T, Markham J, McGee-Minnich L, Antenor-Dorsey J, Hershey T . Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc Natl Acad Sci U S A. 2007; 104(8):2945-9. PMC: 1797149. DOI: 10.1073/pnas.0609833104. View

16.

Toneff T, Hwang S, Chesselet M, Hook V . Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. J Neurosci. 2001; 21(6):1830-7. PMC: 6762596. View

17.

Steffan J, Bodai L, PALLOS J, Poelman M, McCampbell A, Apostol B . Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001; 413(6857):739-43. DOI: 10.1038/35099568. View

18.

Myers R, Leavitt J, Farrer L, Jagadeesh J, McFarlane H, Mastromauro C . Homozygote for Huntington disease. Am J Hum Genet. 1989; 45(4):615-8. PMC: 1683503. View

19.

Takano H, Gusella J . The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci. 2002; 3:15. PMC: 137586. DOI: 10.1186/1471-2202-3-15. View

20.

Reiner A, Albin R, Anderson K, DAMATO C, Penney J, Young A . Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A. 1988; 85(15):5733-7. PMC: 281835. DOI: 10.1073/pnas.85.15.5733. View